Fredric N. Eshelman

Chief Executive Officer, PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC.

Companies

Aravive, Inc.Chair Jan 5, 2022 to Oct 26, 2022¹
HYPERION DEFI, INC.Board member Jan 25, 2018 to Nov 22, 2021²
Aravive, Inc.Board member Apr 10, 2020 to Sep 13, 2021³
G1 Therapeutics, Inc.Board member May 17, 2017 to Jun 12, 2020⁴
Jasper Therapeutics, Inc.Board member Nov 19, 2019 to Nov 19, 2019⁵
Bausch HealthBoard member Mar 15, 2016 to May 3, 2018⁶

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

HYPERION DEFI, INC. HYPD1,299,750 shares⁷$3.7M at $2.84Nov 17, 2021
Aravive, Inc.9,211,769 shares⁸Apr 1, 2022

As of each latest filing. The line shows shares held over time.

Recent filings

Apr 1, 2022Exercised options 4,545,455 shares of Aravive, Inc.⁸
Nov 17, 2021Granted 6,963 shares of HYPERION DEFI, INC.⁷

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARAravive, Inc., Chair
2
SEC EDGARHYPERION DEFI, INC., Board member
3
SEC EDGARAravive, Inc., Board member
4
SEC EDGARG1 Therapeutics, Inc., Board member
5
SEC EDGARJasper Therapeutics, Inc., Board member
6
SEC EDGARBausch Health, Board member
7
SEC EDGARHYPERION DEFI, INC. shares after the filing of Nov 17, 2021
8
SEC EDGARAravive, Inc. shares after the filing of Apr 1, 2022